Core Viewpoint - Xiao-I Corporation is providing an update on its ongoing patent infringement lawsuit against Apple, focusing on allegations of infringement related to core AI technology [1][2]. Legal Proceedings - The Shanghai High People's Court held a second session of hearings on November 1, 2024, after the trial phase concluded on July 31, 2024 [2]. - Apple filed appeals with the Supreme People's Court on September 3, 2024, seeking to invalidate the core AI patents of Xiao-I's variable interest entity (VIE) [2]. Supreme Court Ruling - On March 27, 2026, the Supreme People's Court rejected Apple's application to invalidate Xiao-I's VIE patents, affirming their legality and validity [3]. - This ruling is final and binding under Chinese law, with no further appeal rights available to either party regarding the patent validity [3]. Company Overview - Xiao-I Corporation is a leading cognitive intelligence enterprise in China, specializing in AI solutions such as natural language processing, voice and image recognition, and machine learning [5]. - The company has developed a diverse portfolio of cognitive intelligence technologies since its inception in 2001, aimed at promoting industrial digitization and intelligent transformation [5].

Core Viewpoint - Wall Street analysts are recommending Verizon stock as a defensive investment amid market volatility and economic slowdown concerns, with Barclays raising its price target to $47 from $43, highlighting Verizon's stable revenue and dividend appeal [2][5]. Company Performance - Verizon reported wireless service revenue of $19.998 billion in Q4 2024, marking 18 consecutive quarters of sequential growth [9]. - The company achieved postpaid phone net additions of 568,000, the best performance in over a decade [9]. - Free cash flow for the full year 2024 was $19.822 billion, supporting a quarterly dividend of $0.7075 [9]. Market Context - The VIX index, a measure of market volatility, is currently at 31.05, indicating heightened fear in the market and driving investors towards lower-beta stocks like Verizon [3][8]. - The 10-year Treasury yield is at 4.44%, which typically pressures growth stocks and increases demand for dividend-paying stocks [11]. Analyst Insights - Barclays maintains an Equal Weight rating on Verizon, acknowledging headwinds from declining pricing trends in wireless and broadband but emphasizing the macroeconomic environment as a supportive factor for telecom stocks [5][7]. - Despite the pricing pressure, Verizon's fundamentals and defensive characteristics are seen as attractive for income-focused investors [12]. Stock Performance - Verizon shares have increased by 25.64% year-to-date, contrasting with broader market declines, indicating a successful defensive rotation among investors [10]. - The stock is currently trading above the new price target, suggesting institutional confirmation of the trade rather than a new catalyst [12].

Group 1 - Generation Investment Management's "Global Equity Strategy" for Q4 2025 emphasizes the importance of patient, quality-focused investing amid market uncertainty and distortion [1] - The firm believes that current trends causing underperformance will eventually lead to better results, particularly in sectors related to AI, which are expected to provide long-term value as global computing demands increase [1] - As of December 31, 2025, the Global Equity strategy has total assets under management of USD 21.0 billion [1] Group 2 - Gartner, Inc. (NYSE:IT) reported a one-month return of -3.42% and a 52-week loss of 61.53%, with a closing stock price of $159.14 and a market capitalization of $11.47 billion as of March 30, 2026 [2] - Generation Investment exited its stake in Gartner, Inc. due to concerns that AI was beginning to impact demand for its services, although the firm remains open to future investments in the company [3] - Gartner, Inc. reported revenue of $1.8 billion for Q4 2025, reflecting a 2% year-over-year increase, but is not among the 40 most popular stocks among hedge funds heading into 2026 [5]

Core Insights - JPMorgan Chase has launched the "American Dream Initiative" to enhance economic opportunities across the U.S., focusing initially on small businesses [2][3] - The initiative aims to support 10 million small businesses, increasing from the current 7 million, over the next several years [3] - CEO Jamie Dimon emphasized the need to reignite the American Dream through local investments and effective policies to help individuals achieve home ownership, good jobs, and improved lives [3] Summary by Categories Economic Opportunity - The initiative will provide nearly $80 billion in lending to small businesses over the next decade, increasing access to capital through the bank and partnerships with community development financial institutions [7] - JPMorgan plans to expand its "Coaching for Impact" program to mentor approximately 115,000 small business owners in over 80 cities within the next ten years [7] Workforce Development - The bank intends to hire 1,000 additional small business bankers and double the number of senior business consultants to 150 [7] Payment Modernization - The initiative coincides with a shift in the business payments landscape, where reliance on cash and checks is decreasing in favor of digital payment methods [8] - Research indicates that nearly half of small and medium-sized businesses are interested in reducing their dependence on cash, despite its continued dominance in certain workflows [8][9] - Among Gen Z-owned businesses, over half of payments are made in cash, reflecting the need for immediate transactions [9]

Core Focus - Hilton Food Group is prioritizing growth in its core meat and fresh prepared food businesses while seeking to enhance strategic options for its seafood and plant-based protein segments [1][2] - The company has completed a review of its operations, reinforcing confidence in its core meat operations [1][2] Leadership and Strategy - Executive chair Mark Allen, who will become the new CEO, emphasized that growth will be driven by core capabilities and outlined a clear plan for sustainable long-term growth [2] - The company was established in 1994 and has expanded its market presence to Europe, North America, the Middle East, and Asia Pacific [2] Recent Acquisitions and Performance - Hilton has expanded its product offerings through acquisitions, including Seachill in 2017 and Foppen in 2021, as well as full control of Dalco in the same year [3] - In the latest financial year, Seachill's sales volumes decreased by nearly 7% [3] Challenges and Adjustments - Foppen faced regulatory challenges affecting exports to the US, while Dalco's volumes increased by 8.5%, although it remained unprofitable [4] - The company has placed all three businesses under separate leadership and is limiting future investments in these operations [4] Operational Performance - Hilton's continuing operations saw a volume increase of 0.2%, with stable performance in meat and fresh prepared foods across various regions [5] - Revenue from continuing operations rose by 10.3% to £4.2 billion ($5.56 billion), while operating profit slightly decreased to £90.2 million [6] - Net profit increased from £39.2 million to £47.5 million due to lower tax expenses [6]

Group 1 - BullFrog stock is experiencing a significant surge, trading 17.17% higher at $1.23 [5] - The company has entered into an agreement with a top pharmaceutical company to utilize its AI platform for accelerating drug discovery and clinical development for major depressive disorder (MDD) [2] - The collaboration is seen as third-party validation of BullFrog's proprietary capabilities and may expand into additional areas of the partner's research and development portfolio [3] Group 2 - The agreement provides exclusive access to a target candidate identified through BullFrog's analytical AI platform [2] - BullFrog's integrated platforms, including bfLEAP, bfPREP, and bfARENAS, leverage causal network inference to assist drug developers in identifying and prioritizing targets for complex diseases like MDD [3] - Further details regarding the agreement will be disclosed in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission [4]

Core Viewpoint - Wall Street shows reduced enthusiasm for Micron Technology's stock despite strong earnings, citing concerns over temporary DRAM spot weakness and the impact of TurboQuant memory compression technology on demand [2][3][8]. Financial Performance - Micron reported Q1 FY2026 revenue of $13.64 billion, a 57% increase year-over-year, with non-GAAP EPS of $4.78, surpassing estimates by 21% [2][11]. - Q2 guidance projects revenue of $18.70 billion and non-GAAP EPS of $8.42, indicating continued strength in the memory supercycle [11]. Analyst Ratings and Price Targets - Citi maintained a Buy rating on Micron but reduced its price target from $510 to $425, attributing the cut to temporary market conditions rather than fundamental issues [2][5][9]. - The broader analyst community remains positive, with 38 out of 43 analysts rating it a Buy, and a consensus price target of $527.60, indicating caution despite a generally bullish outlook [9]. Market Reaction - Micron's stock experienced a significant decline of 20% over one week, with a recent drop of 9.92% on the latest trading day, reflecting market uncertainty [3][10][12]. - Despite the recent volatility, the stock is still up 265.23% over the past year, highlighting the contrast between short-term fluctuations and long-term performance [10]. Demand and Technology Concerns - Concerns regarding TurboQuant technology potentially reducing memory demand have been met with skepticism from analysts, who argue that cheaper technology typically drives increased demand in the semiconductor sector [3][8]. - The recent decline in DDR5 16GB DRAM prices by 6% since Micron's earnings report has fueled fears, but analysts believe this is an overreaction to cyclical data rather than a sign of a broken demand thesis [8][12].

Core Viewpoint - Agnico Eagle Mines is making significant investments in Cascadia Minerals, including a private placement and additional unit purchases, as part of its strategy to enhance its geological opportunities in the mining sector [1][2][4]. Investment Details - Agnico Eagle has committed to invest C$5.02 million ($3.6 million) in Cascadia Minerals through a non-brokered private placement, purchasing 19.31 million units at C$0.26 ($0.18) per unit [1]. - In a separate transaction, Agnico Eagle plans to acquire 10 million units from sellers participating in Cascadia's flow-through unit offering, valued at C$2.6 million [2]. Ownership Structure - Post-completion of the transactions, Agnico Eagle will hold approximately 14.21% of Cascadia's issued common shares on a non-diluted basis and about 19.90% on a partially diluted basis after exercising warrants [3]. - Currently, Agnico Eagle does not own any shares or warrants in Cascadia [3]. Investor Rights Agreement - An investor rights agreement will be established, granting Agnico Eagle the right to participate in future equity financings to maintain or increase its ownership up to 19.99% [4]. - Agnico Eagle retains the right to nominate individuals to Cascadia's board, although there is no immediate intention to do so [4]. Strategic Agreements - An earn-in agreement allows Agnico Eagle to earn a 51% interest in Cascadia's Catch property in Yukon, leading to a joint venture agreement where Cascadia will manage the project [5]. - A strategic alliance agreement has been formed for exploring projects within the Stikine Terrane in Yukon, with Agnico Eagle funding exploration activities over three years [6]. Additional Investments - In October 2024, Agnico Eagle committed to a C$55 million ($40 million) investment in ATEX Resources, subscribing for 33.86 million units at C$1.63 each in a significant private placement [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Richtech Robotics Inc. due to allegations of false and misleading statements regarding its relationship with Microsoft, which has led to significant stock price declines [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Richtech to contact them to discuss legal options [1]. - The firm is investigating claims against Richtech and reminds investors of the April 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Richtech misrepresented its relationship with Microsoft, impacting the company's business statements and prospects [4]. Group 2: Stock Performance - On January 29, 2026, Richtech's stock fell by $1.06, or 20.87%, closing at $4.02, following a critical report questioning the company's collaboration with Microsoft [5]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Additional Information - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding Richtech's conduct [7].

Core Insights - NeuroSense Therapeutics reported significant advancements in its lead drug candidate PrimeC, transitioning from a Phase 2b program to a late-stage clinical asset with a clear regulatory path [2][3] - The company demonstrated a 33% slowing in disease progression in ALS patients over 18 months and achieved a 65% reduction in the risk of death with a median survival benefit of over 14 months [2][4][6] - PrimeC's results were published in JAMA Neurology, validating its clinical and biological activity [5][6] Business Highlights from 2025 - NeuroSense advanced PrimeC into a late-stage clinical asset with FDA clearance for the PARAGON Phase 3 trial in ALS [3][6] - The Phase 2b PARADIGM study showed a significant reduction in ALS-related complications and supported PrimeC's potential as a disease-modifying therapy [2][3] - The company completed commercial-scale manufacturing and engaged with Health Canada for regulatory strategy [3] Recent Developments and First Quarter 2026 Highlights - In 2026, NeuroSense reported statistically significant survival data from its Phase 2b study, reinforcing PrimeC's clinical package [4][5] - The company expanded its scientific visibility through presentations at international conferences and strengthened its intellectual property portfolio with new patents [5][6] Financial Results - Research and development expenses for 2025 were $6.2 million, an increase of 8.8% from 2024, primarily due to higher share-based payment expenses [7] - General and administrative expenses rose to $4.9 million, a 16.6% increase from the previous year, also driven by share-based compensation [8] - As of December 31, 2025, NeuroSense had cash of approximately $0.2 million, down from $3.4 million in 2024 [8][10] Consolidated Financial Position - Total assets as of December 31, 2025, were $1.028 billion, a decrease from $4.575 billion in 2024 [10][13] - Total liabilities increased to $2.588 billion from $1.992 billion in 2024, indicating a growing financial burden [12][13] - The company reported a net loss of $11.125 million for 2025, compared to a loss of $10.210 million in 2024 [13][14]